Assenagon Asset Management S.A. Increases Stock Position in Cerus Corporation $CERS

Assenagon Asset Management S.A. increased its holdings in Cerus Corporation (NASDAQ:CERS) by 29.3% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,583,702 shares of the biotechnology company’s stock after buying an additional 358,548 shares during the period. Assenagon Asset Management S.A.’s holdings in Cerus were worth $2,518,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of CERS. Focus Partners Advisor Solutions LLC boosted its holdings in shares of Cerus by 65.2% in the second quarter. Focus Partners Advisor Solutions LLC now owns 19,930 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 7,866 shares during the period. Dynamic Technology Lab Private Ltd bought a new stake in shares of Cerus during the 1st quarter valued at $32,000. HUB Investment Partners LLC purchased a new stake in Cerus during the 2nd quarter worth about $42,000. Captrust Financial Advisors boosted its stake in Cerus by 89.7% in the 2nd quarter. Captrust Financial Advisors now owns 31,109 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 14,709 shares during the period. Finally, Easterly Investment Partners LLC purchased a new position in Cerus during the 2nd quarter valued at about $63,000. Institutional investors own 78.37% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on CERS shares. Wall Street Zen raised shares of Cerus from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cerus in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $4.00.

Cerus Stock Performance

Cerus stock opened at $2.06 on Wednesday. Cerus Corporation has a fifty-two week low of $1.12 and a fifty-two week high of $2.26. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.29 and a current ratio of 1.89. The stock has a market cap of $395.71 million, a P/E ratio of -25.75 and a beta of 1.55. The firm’s fifty day moving average price is $1.73 and its 200-day moving average price is $1.50.

Cerus (NASDAQ:CERS) last announced its earnings results on Thursday, November 6th. The biotechnology company reported $0.00 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.02. Cerus had a negative net margin of 8.01% and a negative return on equity of 27.58%. The company had revenue of $60.24 million during the quarter, compared to analyst estimates of $55.12 million. On average, equities research analysts expect that Cerus Corporation will post -0.08 earnings per share for the current fiscal year.

Cerus Profile

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.